Conduit Pharmaceuticals (CDT) Company Overview

Conduit is planning how to effectively integrate an advanced platform-driven approach powered by artificial intelligence and cybernetics to expedite drug development, while continuing to advance its portfolio of proprietary assets to clinic. NAPLES, Fla.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-100 reverse stock split of the Company's common stock.

Revenue of $12.7 million and earnings per share of $0.14 impacted by reduced project activity due to a slowdown in the PRC economy Revenue of $12.7 million and earnings per share of $0.14 impacted by reduced project activity due to a slowdown in the PRC economy

Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring. This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company's lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders.

SAN DIEGO and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) --   Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a broad spectrum of autoimmune disorders.

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties.

Conduit Pharmaceuticals (NASDAQ: CDT ) stock is up on Wednesday following a shareholder update concerning a major investor in the company. New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited holds a 14.8% stake in CDT stock.

Initial joint project in Fuzhou expected to generate an increase in revenue by more than 50% over next three years Initial joint project in Fuzhou expected to generate an increase in revenue by more than 50% over next three years